MINK疗法报告,使用新的细胞疗法,对高级睾丸癌病人完全解除了这种疾病。 MiNK Therapeutics reports complete remission in advanced testicular cancer patient using their new cell therapy.

MiNK治疗机构宣布了一起开创性案例, 一名患有先进的抗治疗性抗睾丸癌的病人在接受实验性非现成的iNKT细胞疗法(agenT-797)后, MiNK Therapeutics announced a groundbreaking case of a patient with advanced, treatment-resistant testicular cancer achieving complete remission after receiving their experimental off-the-shelf iNKT cell therapy, agenT-797, alongside nivolumab. 这种治疗是经过良好许可的,导致公司股票价格大幅度上涨。 The treatment, which was well-tolerated, has led to a significant increase in the company's stock price. AgenT-797目前正在临床试验各种癌症,包括胃癌,这一案例的成功可以扩大其在治疗其他固态肿瘤方面的用途。 AgenT-797 is currently in clinical trials for various cancers, including gastric cancer, and the success of this case could expand its use in treating other solid tumors.